PLYMOUTH MEETING, Pa.,
March 2, 2020 /PRNewswire/ -- Inovio
Pharmaceuticals, Inc. (NASDAQ: INO) announced today that fourth
quarter and full year 2019 financial results will be released after
the market close on March 12, 2020.
Following the release, the Company will host a live conference call
and webcast at 4:30 p.m. ET, to
provide a general business update and financial results for the
fourth quarter and full year 2019.
A live and archived version of the audio presentation will be
available online at
http://ir.inovio.com/investors/events/default.aspx. This is a
listen-only event but will include a live Q&A with
analysts.
Telephone replay will be available approximately one hour after
the call at 877-344-7529 (US toll free) or 412-317-0088
(international toll) using replay access code 10139836.
About Inovio Pharmaceuticals, Inc.
Inovio is a biotechnology company focused on rapidly bringing to
market precisely designed DNA medicines to treat, cure, and protect
people from diseases associated with HPV, cancer, and infectious
diseases. Inovio is the first and only company to have clinically
demonstrated that a DNA medicine can be delivered directly into
cells in the body via a proprietary smart device to safely produce
a robust immune response to destroy and clear high-risk HPV 16 and
18, which are responsible for 70% of cervical cancer, 90% of anal
cancer and 69% of vulvar cancer. In addition to HPV, Inovio's
optimized plasmid design and delivery technology have been
demonstrated to consistently activate robust and fully functional T
cell and antibody responses against targeted cancers and pathogens.
Inovio's most advanced clinical program, VGX-3100, is in Phase 3
development for the treatment of HPV-related cervical pre-cancer.
Also in development are Phase 2 immuno-oncology programs targeting
HPV-related cancers, GBM, and prostate cancer, as well as
externally funded vaccine development programs in Zika, MERS,
Lassa, HIV, and COVID-19. Partners and collaborators include
ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates
Foundation, Coalition for Epidemic Preparedness Innovations (CEPI),
Defense Advanced Research Projects Agency, GeneOne Life Science,
HIV Vaccines Trial Network, Medical CBRN Defense Consortium (MCDC),
National Cancer Institute, National Institutes of Health, National
Institute of Allergy and Infectious Diseases, Regeneron,
Roche/Genentech, University of
Pennsylvania, Walter Reed Army Institute of Research, and
The Wistar Institute. For more information, visit
www.inovio.com.
* * * *
This press release contains certain forward-looking
statements relating to our business, including our plans to develop
DNA medicines, our expectations regarding our research and
development programs, as well as commercialization activities,
including the planned initiation and conduct of clinical trials,
the availability and timing of data from those trials and our
commercialization strategy and tactics. Actual events or results
may differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, clinical trials, product development programs and
commercialization activities and outcomes, the availability of
funding to support continuing research and studies in an effort to
prove safety and efficacy of electroporation technology as a
delivery mechanism or develop viable DNA medicines, our ability to
support our pipeline of DNA medicine products, the ability of our
collaborators to attain development and commercial milestones for
products we license and product sales that will enable us to
receive future payments and royalties, the adequacy of our capital
resources, the availability or potential availability of
alternative therapies or treatments for the conditions targeted by
us or our collaborators, including alternatives that may be more
efficacious or cost effective than any therapy or treatment that we
and our collaborators hope to develop, issues involving product
liability, issues involving patents and whether they or licenses to
them will provide us with meaningful protection from others using
the covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
we can finance or devote other significant resources that may be
necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of our technology by potential
corporate or other partners or collaborators, capital market
conditions, the impact of government healthcare proposals and other
factors set forth in our Annual Report on Form 10-K for the year
ended December 31, 2018, our
Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and other filings we make
from time to time with the Securities and Exchange Commission.
There can be no assurance that any product candidate in our
pipeline will be successfully developed, manufactured or
commercialized, that final results of clinical trials will be
supportive of regulatory approvals required to market products, or
that any of the forward-looking information provided herein will be
proven accurate. Forward-looking statements speak only as of the
date of this release, and we undertake no obligation to update or
revise these statements, except as may be required by law.
CONTACTS:
|
|
Investors:
|
Ben Matone,
484-362-0076, ben.matone@inovio.com
|
Media:
|
Jeff Richardson,
267-440-4211, jrichardson@inovio.com
|
View original
content:http://www.prnewswire.com/news-releases/inovio-pharmaceuticals-to-report-fourth-quarter-and-full-year-2019-financial-results-on-march-12-2020-301014056.html
SOURCE Inovio Pharmaceuticals, Inc.